Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Elanco Animal Health Incorporated (NYSE:ELAN - Get Rating) saw unusually large options trading on Tuesday. Traders bought 18,238 call options on the company. This represents an increase of 324% compared to the average volume of 4,302 call options.Elanco Animal Health Trading Up 2.1 %
NYSE:ELAN traded up $0.26 on Tuesday, reaching $12.82. The company's stock had a trading volume of 138,349 shares, compared to its average volume of 7,307,364. Elanco Animal Health has a 12-month low of $12.19 and a 12-month high of $35.00. The stock has a 50 day moving average price of $16.43 and a 200 day moving average price of $20.96. The firm has a market cap of $6.08 billion, a price-to-earnings ratio of -35.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.92. The company has a quick ratio of 1.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.84.
Elanco Animal Health (NYSE:ELAN - Get Rating) last announced its earnings results on Monday, August 8th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.10. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 3.77% and a positive return on equity of 7.40%. The firm's revenue for the quarter was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 EPS. On average, equities analysts anticipate that Elanco Animal Health will post 1.09 EPS for the current fiscal year. Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ELAN. Stifel Nicolaus reduced their price target on Elanco Animal Health from $30.00 to $22.00 and set a "hold" rating on the stock in a research report on Friday, June 24th. The Goldman Sachs Group downgraded shares of Elanco Animal Health from a "buy" rating to a "sell" rating and cut their price target for the stock from $32.00 to $19.00 in a report on Thursday, July 21st. Piper Sandler lowered their price target on shares of Elanco Animal Health from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, August 16th. JPMorgan Chase & Co. cut Elanco Animal Health from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $28.00 to $24.00 in a research report on Tuesday, August 16th. Finally, Morgan Stanley cut shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $37.00 to $22.00 in a research note on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $21.00.Insider Buying and Selling
In other Elanco Animal Health news, insider Rajeev A. Modi bought 6,700 shares of Elanco Animal Health stock in a transaction dated Friday, September 9th. The shares were purchased at an average cost of $14.90 per share, for a total transaction of $99,830.00. Following the acquisition, the insider now directly owns 41,157 shares in the company, valued at approximately $613,239.30. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 30,000 shares of the firm's stock in a transaction that occurred on Friday, September 9th. The stock was purchased at an average cost of $14.54 per share, with a total value of $436,200.00. Following the purchase, the chief executive officer now owns 30,000 shares of the company's stock, valued at $436,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev A. Modi acquired 6,700 shares of the company's stock in a transaction that occurred on Friday, September 9th. The shares were acquired at an average price of $14.90 per share, with a total value of $99,830.00. Following the acquisition, the insider now owns 41,157 shares in the company, valued at $613,239.30. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 56,700 shares of company stock worth $839,630. Corporate insiders own 6.40% of the company's stock. Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Herold Advisors Inc. acquired a new position in Elanco Animal Health during the first quarter worth about $26,000. Tcwp LLC acquired a new position in shares of Elanco Animal Health during the 1st quarter worth $29,000. IndexIQ Advisors LLC purchased a new stake in shares of Elanco Animal Health in the 1st quarter worth about $32,000. CKW Financial Group grew its stake in Elanco Animal Health by 36.4% in the 1st quarter. CKW Financial Group now owns 1,500 shares of the company's stock valued at $39,000 after acquiring an additional 400 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Elanco Animal Health by 147.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,556 shares of the company's stock worth $41,000 after acquiring an additional 928 shares during the last quarter. Institutional investors and hedge funds own 98.15% of the company's stock. About Elanco Animal Health (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.Featured StoriesGet a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)3 Safe Earnings Plays for a Risk-Off MarketTyson Foods Takes a Lickin’ and Keeps on Tickin’ LowerSmall-Cap Catalyst Pharma Is Among Market's Best Price Performers3 Stocks Growing Their Businesses for 2023China-Based EV Maker BYD Set For Big European, Japanese Expansion
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Kirk McDonald shares three stocks from different industries with different market caps and explains why each is a holding in his portfolio.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.